Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Chinese Patent Office
Covington
Daiichi Sankyo
Accenture
McKesson
Queensland Health
Harvard Business School
Mallinckrodt
Novartis
Johnson and Johnson

Generated: January 16, 2018

DrugPatentWatch Database Preview

Details for Patent: 5,972,916

« Back to Dashboard

Summary for Patent: 5,972,916
Title: Compositions containing the nonprescription combination of acetaminophen, aspirin and caffeine to alleviate the pain and symptoms of migraine
Abstract:The invention provides a safe and economical nonprescription combination of acetaminophen, aspirin and caffeine (APAP/ASA/CAF) for use in treating migraine pain and the cluster of symptoms characteristic of migraine attack, such as nausea, photophobia, phonophobia and functional disabilities. The use of the APAP/ASA/CAF combination is also effective in aborting the prodrome phase of a migraine attack.
Inventor(s): Armellino; Joseph (Chester, NJ), Koslo; Randy (West Windsor Township, NJ)
Assignee: Bristol-Myers Squibb Company (New York, NY)
Application Number:09/021,284
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Drugs Protected by US Patent 5,972,916

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Glaxosmithkline Cons EXCEDRIN (MIGRAINE) acetaminophen; aspirin; caffeine TABLET;ORAL 020802-001 Jan 14, 1998 OTC Yes Yes ➤ Subscribe ➤ Subscribe TREATING MIGRAINE PAIN AND ONE OR MORE OF A CLUSTER OF SYMPTOMS CHARACTERISTIC OF A MIGRAINE ATTACK SYMPTOMS BEING SELECTED FROM PHOTOPHOBIA, PHONOPHOBIA NAUSEA AND FUNCTIONAL DISABILITY ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 5,972,916

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Malaysia 121730 ➤ Subscribe
Spain 2198725 ➤ Subscribe
European Patent Office 0994714 ➤ Subscribe
Denmark 0994714 ➤ Subscribe
Germany 69814636 ➤ Subscribe
Canada 2296492 ➤ Subscribe
Portugal 994714 ➤ Subscribe
Taiwan 565447 ➤ Subscribe
Australia 8170598 ➤ Subscribe
Austria 240105 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Federal Trade Commission
Julphar
Deloitte
McKinsey
Healthtrust
AstraZeneca
US Army
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot